SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced the launch of its Tapestri® Genome Integrity CNV Solution. This new product is the only single-cell high-throughput solution for measuring genome-wide copy number variants (CNVs) on the market and is designed to fulfill important needs in the critical areas of therapeutic development oncology research..

加利福尼亚州南旧金山（商业新闻短讯）--精准医学单细胞多组学解决方案的领导者Mission Bio今天宣布推出Tapestri®Genome Integrity CNV解决方案。该新产品是市场上唯一用于测量全基因组拷贝数变异（CNV）的单细胞高通量解决方案，旨在满足治疗发展肿瘤学研究关键领域的重要需求。。

While genome-editing and stem cell therapies continue to harbor tremendous promise for treating complex diseases but have encountered safety concerns associated with genomic instability. The latest FDA guidance suggests that assessment of genomic integrity should include chromosomal abnormalities like CNVs (i.e., duplications and deletions) as indicators of clinical safety.

虽然基因组编辑和干细胞疗法在治疗复杂疾病方面仍然具有巨大的前景，但也遇到了与基因组不稳定性相关的安全问题。最新的FDA指南建议，基因组完整性的评估应包括染色体异常，如CNV（即重复和缺失），作为临床安全性的指标。

Conventional methods of assessing genomic instability such as g-banding fail to provide adequate answers due to their low throughput, as they may not analyze enough cells to detect aberrations. Oncology researchers have faced similar issues unlocking the potential of CNVs to serve as prognostic or therapeutic markers associated with tumor evolution, immune evasion, and therapeutic resistance.

传统的评估基因组不稳定性的方法（例如g带）由于吞吐量低而无法提供足够的答案，因为它们可能无法分析足够的细胞来检测畸变。肿瘤学研究人员面临着类似的问题，这些问题释放了CNV作为与肿瘤进化，免疫逃避和治疗抵抗相关的预后或治疗标志物的潜力。

Existing bulk techniques provide only a limited view of CNV-based clonal architecture..

现有的批量技术仅提供了基于CNV的克隆体系结构的有限视图。。

Mission Bio’s Tapestri Genome Integrity CNV Solution enables both CGT developers and oncology researchers with high-throughput, single-cell multiomic analysis of genome-wide CNVs, combined with automated reporting and multiplexing capabilities to ensure even more accessibility. Compared to current methods, the solution equips CGT developers with improved assay throughput to uncover potentially adverse chromosomal events, while simultaneously measuring genome editing outcomes.

Mission Bio的Tapestri Genome Integrity CNV解决方案使CGT开发人员和肿瘤学研究人员能够对全基因组CNV进行高通量单细胞多组学分析，并结合自动报告和多路复用功能，以确保更多的可访问性。与目前的方法相比，该解决方案为CGT开发人员提供了改进的测定通量，以发现潜在的不良染色体事件，同时测量基因组编辑结果。

For oncology researchers, the solution enables the assessment of cell-to-cell aneuploidy and CNV events across the genome with the potential to co-measure SNVs and focal CNVs. Tapestri enables these researchers the rapid characterization of clonal heterogeneity behind tumorigenesis and therapy resistance..

对于肿瘤学研究人员来说，该解决方案可以评估整个基因组中的细胞间非整倍性和CNV事件，并有可能共同测量SNV和局灶性CNV。Tapestri使这些研究人员能够快速表征肿瘤发生和治疗耐药性背后的克隆异质性。。

“While working on a new way of investigating chromosomal instability and aneuploidy within tumors, we found that Mission Bio’s Tapestri Platform was able to provide the combination of high throughput and high sensitivity we needed,” said Dr. Teresa Davoli of the NYU School of Medicine’s Institute for Systems Genetics and Department of Biochemistry and Molecular Pharmacology.

纽约大学医学院系统遗传学研究所和生物化学与分子药理学系的Teresa Davoli博士说：“在研究肿瘤内染色体不稳定性和非整倍性的新方法时，我们发现Mission Bio的Tapestri平台能够提供我们所需的高通量和高灵敏度的结合。”。

“Mission Bio’s Tapestri platform gave our team the flexibility and customizability necessary to push our understanding of aneuploidy across thousands of single cells simultaneously.” For details of her study see “KaryoTap Enables Aneuploidy Detection in Thousands of Single Human Cells.”.

“Mission Bio的Tapestri平台为我们的团队提供了必要的灵活性和可定制性，可以同时推动我们对数千个单细胞非整倍性的理解。”有关她的研究细节，请参阅“NucleoAP可以在数千个单细胞中检测非整倍性。”。

“The launch of the Tapestri Genome Integrity CNV Solution represents a significant advancement in therapeutic development and cancer research,” said Vanee Pho-Conners PhD, Senior Director of Product Management at Mission Bio. “By offering genome-wide CNV analysis at the single-cell level, we're bridging a critical safety gap for CGT developers, who require precise genomic stability measurements to ensure the safety and efficacy of their therapies.

Mission Bio产品管理高级总监Vanee Pho Conners博士说：“Tapestri Genome Integrity CNV解决方案的推出代表了治疗开发和癌症研究的重大进步。通过在单细胞水平上提供全基因组CNV分析，我们弥合了CGT开发人员的关键安全差距，他们需要精确的基因组稳定性测量来确保其治疗的安全性和有效性。

This innovation highlights our commitment to equipping researchers with the most comprehensive tools to drive transformative breakthroughs in treatment.”.

这项创新突显了我们致力于为研究人员提供最全面的工具，以推动治疗领域的变革性突破。”。

The assay will be a key focus of Mission Bio at the 31st annual European Society of Gene & Cell Therapy Meeting, taking place Oct. 22-25 in Rome. For more information, please visit booth B24 or https://missionbio.com/genome-integrity-assay-development/.

在10月22日至25日于罗马举行的第31届欧洲基因与细胞治疗学会年会上，Mission Bio将重点关注该检测方法。欲了解更多信息，请访问B24展位或https://missionbio.com/genome-integrity-assay-development/.

About Mission Bio

关于Mission Bio

Mission Bio is a leading life science company, specializing in the advancement of single-cell DNA and multiomics analysis. The company’s Tapestri Platform is unique in its capabilities, offering an unparalleled level of granularity and precision that is critical for complex research areas such as cancer studies, pharmaceutical development, and advanced cell and gene therapies.

Mission Bio是一家领先的生命科学公司，专门从事单细胞DNA和多组学分析的发展。该公司的Tapestri平台功能独特，提供无与伦比的粒度和精确度，这对于癌症研究、药物开发以及先进的细胞和基因治疗等复杂研究领域至关重要。

Unlike traditional methods such as bulk sequencing, Tapestri provides a level of precision that opens the door for more tailored and effective treatment strategies. Researchers globally depend on Tapestri to identify rare cell populations, understand mechanisms of therapeutic resistance and response, and establish key quality metrics for next-generation medical treatments.

与批量测序等传统方法不同，Tapestri提供了一定程度的精确度，为更定制和有效的治疗策略打开了大门。全球研究人员依靠Tapestri来识别稀有细胞群，了解治疗抵抗和反应的机制，并为下一代医学治疗建立关键的质量指标。

Founded in 2014, Mission Bio has secured investment from firms including Mayfield Fund, Novo Growth, Cota Capital, and Agilent Technologies. With the Tapestri Platform, Mission Bio is setting the standard in the field, contributing significantly to the progress of personalized medicine and targeted therapies.

凭借Tapestri平台，Mission Bio正在该领域树立标准，为个性化医疗和靶向治疗的进步做出了重大贡献。